The effect of neuroprotectors is directed to the key components of nerve cell destructive processes of vascular, traumatic, or toxic etiologies. Phosphatidylcholines, gingko biloba-based agents, and a combination of B vitamins and folic acid, which are contained in Cerebrovin, may act as a neuroprotector. Objective — to reveal the possible effect of Cerebrovin on the degree of decline in cognitive functions and motor dexterity, including a typing speed test. Subject and methods. Patients with chronic cerebral ischemia (CCI) with mild and moderate cognitive impairment (MiCI and MoCI) were followed up. The Montreal Cognitive Assessment (MoCA), the Münsterberg test, the Trail Making Test (TMT), and original hand motor dexterity tests were used. The investigation enrolled 30 patients aged 55—75 years (mean age, 68.0±5.4 years) with CCI. All the participants were divided into two groups: 1) MiCI (n=18) and 2) MoCI (n=12). One or two Cerebrovin tablets were daily given during 4 weeks for MiCI and MoCI, respectively. Results. There were statistical differences between the groups in the baseline indicators: MoCA (26.6±1.6 vs 24.8±1.9, respectively; p=0.005), TMT-B (114.7±42.9 sec vs 147.8±49.6 sec, respectively; p=0.031), typing speed test (31.3±5.9 sec vs 41.0±6.5 sec, respectively; p=0.000). Both groups also showed statistical differences in MoCA scores in the MiCI group (26.6±1.6 and 27.8±1.5 before and after, respectively; p=0.014) and in the MoCI group (24.8±1.9 and 26.3±1.6 before and after, respectively; p=0.035), recognition of 25 words in the Münsterberg test in the entire group (22.7±1.8 and 23.7±1.0 before and after, respectively; p=0.011); the results were obtained due to the changes in the MiCI group (22.6±2.2 and 23.7±0.6 before and after, respectively; p=0.015). Conclusion. After 4-week therapy with Cerebrovin, there were more marked changes in MiCI. Cerebrovin can be recommended as part of combination therapy in patients with cerebrovascular diseases in an outpatient setting.